Two New Antiseizure Drugs: A Pharmacist Perspective

Published Online: Tuesday, March 20, 2012
In this podcast, part of’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of, interviews Barry Gidal, PharmD, professor of pharmacy and neurology at the University of Wisconsin, about two new antiepileptic drugs (AEDs): ezogabine and perampanel.
Dr. Gidal explains that ezogabine, which was approved by the FDA in June 2011, helps to reduce seizure activity by keeping the potassium channels of neurons open, while perampanel, which has not yet been approved, blocks the stimulation of 1 of 3 key neuronal receptors that are thought to be key in starting and continuing seizures. He explains that both medications have shown very good promise in reducing seizure activity in patients who have failed to respond to multiple other AEDs and do not appear to have serious side effects or drug interaction problems.
To listen to the podcast, click here and scroll down to the October 28, 2011, episode.
Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues